Cytosorbents (CTSO) EBIAT (2016 - 2025)
Historic EBIAT for Cytosorbents (CTSO) over the last 15 years, with Q3 2025 value amounting to -$3.2 million.
- Cytosorbents' EBIAT fell 1452.31% to -$3.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$10.3 million, marking a year-over-year increase of 4794.26%. This contributed to the annual value of -$20.7 million for FY2024, which is 2915.81% up from last year.
- Cytosorbents' EBIAT amounted to -$3.2 million in Q3 2025, which was down 1452.31% from $1.9 million recorded in Q2 2025.
- Over the past 5 years, Cytosorbents' EBIAT peaked at $1.9 million during Q2 2025, and registered a low of -$12.2 million during Q3 2022.
- Moreover, its 5-year median value for EBIAT was -$6.2 million (2023), whereas its average is -$5.8 million.
- Per our database at Business Quant, Cytosorbents' EBIAT crashed by 127327.47% in 2021 and then surged by 14534.23% in 2025.
- Quarter analysis of 5 years shows Cytosorbents' EBIAT stood at -$9.3 million in 2021, then soared by 91.77% to -$766126.0 in 2022, then crashed by 758.12% to -$6.6 million in 2023, then fell by 15.1% to -$7.6 million in 2024, then skyrocketed by 58.11% to -$3.2 million in 2025.
- Its last three reported values are -$3.2 million in Q3 2025, $1.9 million for Q2 2025, and -$1.5 million during Q1 2025.